ABOUT

The annual incidence rate of Bacterial Vaginosis and Candida albicans is 29% for women in the US between the ages of 15 and 44.  Another 45% of these women suffer a second infection.  Left untreated or improperly treated, Bacterial Vaginosis contributes to the spread of STD and can damage reproductive organs.  

QXD provides a Quorum Sensing solution for the identification of either Bacterial Vaginosis vs Candida albicans in the patient/provider setting without the delay of waiting on invasive wet testing and culture testing.  QXD is the first solution to the unmet need of diagnosing BV/CV infection.  We care about female health.

QXD Quorum Sensing differentiates Bacterial Vaginosis from Candida albicans for early and proper treatment.

QXD testing uses lateral flow technology with a proprietary combination of antigens, antibodies, proteins, and nitrocellulous membranes to identify microbial infection via their Quorum Signals.

A four-minute solution:  QXD's Quorum Sensing platform is the faster, non-invasive, and convenient solution versus labor-intensive traditional diagnosic methods.